MEET OUR BOARD
Carol McDaid serves as Principal at Capitol Decisions, Inc. Capitol Decisions has a special expertise in addiction and mental health policy. For over two decades, Ms. McDaid has worked with leading addiction and mental health provider and consumer organizations to refine public policy addressing addiction and mental health. With nearly 30 years of Federal legislative experience in Washington, Ms. McDaid provides clients with public affairs consulting on issues that span the breadth of health care, including behavioral health, Medicare, Medicaid, and private sector reimbursement issues. Ms. McDaid served as a strategist and advisor to the Parity NOW Coalition, which was influential in passage of the 2008 “Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act.” This landmark legislation requires insurers to treat addiction, mental, and physical health problems equally. To make a difference at the local level, in 2004, Ms. McDaid co-founded the McShin Foundation in Richmond, Virginia with her husband, John Shinholser. McShin is a leading non-profit, full-service recovery community organization committed to serving individuals and families in and seeking recovery from addiction in the State of Virginia. McShin offers peer-to-peer recovery support services that include recovery coaching, housing, and justice based recovery supports. Because Ms. McDaid personally struggled with addiction, she understands the challenges, political and personal, of dealing with alcohol and drug issues. She is a founding member of Faces and Voices of Recovery and is a board member of Young People in Recovery.
Deni Carise, Ph.D.
Deni Carise, Ph.D. is a Clinical Psychologist and part of the recovery community for over 30 years. She is currently Chief Scientific Officer of Recovery Centers of America (RCA). RCA is the first provider of substance abuse and recovery support services in the country dedicated to creating neighborhood-based treatment and recovery campuses that include detoxification, residential, partial hospital, intensive and traditional outpatient, and family services all available on one campus. From March 2016 – March 2018, they opened 6 such campuses, 2 in MA and MD, and 1 each in PA and NJ.
Deni has held similar positions at CRC Health Group, providing behavioral health services to more than 42,000 men, women and teens every day at more than140 programs in 33 states and Phoenix House, a nonprofit substance abuse treatment provider with over 100 programs in 10 states where Dr Carise developed national standards for clinical care, Clinical Toolkits for over 30 evidence-based practices, and helped usher in a new era of care to position the company to successfully address changes secondary to healthcare reform. Dr Carise was also Chief Clinical Advisor for Sierra Tucson, a premier facility treating substance abuse, pain, mood, eating and trauma disorders.
Dr Carise was an NIH-funded scientist and Director of the Treatment Systems Section at Treatment Research Institute. At TRI from 1994 to 2010, she made significant advances in the quality of substance abuse treatment through the development, application, and research of new interventions, systems, and technologies through receipt of numerous NIH and other federal grants. She has published over 100 articles, books, and chapters.
Dr Carise is currently an Adjunct Assistant Professor at the University of Pennsylvania, Perelman School of Medicine (since 1997). She has been affiliated with UPENN since completing a NIDA Post-Doctoral fellowship at the Center for Studies of Addiction in the Department of Psychiatry from 1994-1996. She earned both her Bachelor’s Degree and Doctorate in Clinical Psychology from Hahnemann (now Drexel) University, she interned at Homewood (part of the Johns Hopkins Health system) and Union Memorial hospitals in behavioral medicine.
She has worked extensively internationally, with treatment providers in Nigeria, Mexico, Thailand, Egypt, Greece, Singapore, Brazil, and China and numerous other countries to help develop national systems that integrate scientifically-validated tools into clinical treatment delivery.
Committed to the accurate portrayal of addiction, treatment, and recovery in the media, Dr Carise consulted on Martin Scorsese’s film, Wolf of Wall Street, working with the primary actors on depicting characters who are abusing cocaine and other drugs, and has been instrumental in other movies and screen plays accurately depicting drug abuse, treatment and recovery. She has also been featured in segments of Nightline, MSNBC, Fox News, ABC, CBS and NBS evening news, Access Hollywood, New York news and many Federally-funded Web-casts and has also been quoted in popular newsprint media such as US News and World Report, Fox News, Wall Street Journal, Alcohol and Drug Abuse Weekly, NIDA Notes and others. Dr. Carise has presented over 200 lectures by invitation (approximately 35 internationally). She is also a frequent blogger on Huffington Post (http://www.huffingtonpost.com/deni-carise) on topics including treatment, recovery, prescription drug abuse, the media’s portrayal of drug problems, Healthcare Reform, Parity, and emerging drug trends.
Ben A. Guill
Ben A. Guill is managing partner and co-founder of White Deer Energy, an investment firm with offices in Houston and New York. During that period, he helped the firm and the funds it raised grow from $812 million with seven investment professionals to $7.8 billion with 35 investment professionals. Mr. Guill managed First Reserve’s Houston office, focusing on deal origination, investment analysis, negotiation of acquisitions and management of portfolio companies.
Prior to 1998, he was Co-Head of Investment Banking at Simmons & Company International, a leading specialized investment bank serving the energy industry. Mr. Guill joined Simmons in 1980 and served 19 years in corporate finance, working primarily on mergers and acquisitions, financings and corporate restructuring. Prior to his service with Simmons, he was an Associate at Blyth Eastman Dillon.
Mr. Guill is currently a Director of National Oilwell Varco (NYSE:NOV). He serves on the Board of MD Anderson Cancer Center in Houston and the Houston region of Teach for America. Mr. Guill holds an MBA in Finance from Wharton School and a BA in English from Princeton University.
Levenson strives to improve the lives of millions of individuals and families. He has established MAP as the nation’s leader in the provision of tech-enabled PEER and professional services to improve clinical and financial treatment outcomes for healthcare plans, treatment providers, and healthcare consumers. MAP is driven to optimize the care continuum and its data suggests that this is the foundation for improving healthcare delivery in this country. Levenson is also a Board Member at The Levenson Foundation and a founding member of Tri-Private Capital.
Steve Sost serves as VP, Internal Communications, at Impax Laboratories, where he brings more than 15 years of experience in M&A communications, global branding; internal communications; and employee culture design and engagement. Most recently, Steve served as Global Lead, Employee Engagement, at Merck. Prior to Merck, Steve spent six years at Allergan (previously known as Actavis) as Executive Director, Corporate Communications, where he led global internal communications and spearheaded the company’s commitment to addiction awareness. Steve also spent considerable time as a partner with Mayr Communications, a strategic communications firm, advising various organizations, including the Generic Pharmaceutical Association (GPhA). Steve received his B.A. degree from Marist College.
As an early supporter and champion of YPR, Charlie Mayr is remembered by YPR as a memorial board member in perpetuity so his spirit, love of life and passion for our cause will always be with us. Mayr was appointed Chief Communications Officer of Actavis on April 27, 2012. Charlie joined Watson as Senior Vice President, Corporate Affairs in September 2009. Prior to joining Watson, Charlie operated an advertising and public relations consulting company from 1998 to 2009, serving such clients as Watson, the Generic Pharmaceutical Association (GPhA), Barr Pharmaceuticals and a variety of professional associations and consumer products and service companies. Prior to starting his consultancy business, he served as Director of Corporate Communications for Barr Pharmaceuticals, Inc. from 1994 to 1998. Prior to joining Barr, he served as Director of Global Communications from 1990 to 1994 for Sterling Drug Inc., the global brand and consumer health products pharmaceutical subsidiary of Kodak. Charlie began his career as a broadcast and print journalist and received a B.A. in journalism from New York University.